Investment Analysts Call On Western Drug Titans To Become More Transparent On Absolute Sales, Profit Levels In Emerging Markets
This article was originally published in PharmAsia News
Executive Summary
BEIJING - The globe's leading pharmaceutical players should become more transparent about precise sales and profit levels across emerging markets, including China, rather than issue vague statements about double-digit growth in these regions without providing base figures, according to investment analysts
You may also be interested in...
AstraZeneca, GlaxoSmithKline, Merck: Emerging Markets Earnings Roundup (Part 2 of 3)
A push in emerging markets continued in the second quarter with Big Pharma reporting flat U.S. sales and a challenging payer environment in Europe, with many reallocating resources from Europe and the U.S. to Asia and other emerging markets and seeking partnerships in those geographies. Analysts boosted earnings per share numbers to companies that disclosed detailed emerging markets sales data, such as AstraZeneca, which started the trend in Q1. As a recurring feature, PharmAsia News combs through quarterly earnings reports to bring together the earning season's Asia highlights.
AstraZeneca, GlaxoSmithKline, Merck: Emerging Markets Earnings Roundup (Part 2 of 3)
A push in emerging markets continued in the second quarter with Big Pharma reporting flat U.S. sales and a challenging payer environment in Europe, with many reallocating resources from Europe and the U.S. to Asia and other emerging markets and seeking partnerships in those geographies. Analysts boosted earnings per share numbers to companies that disclosed detailed emerging markets sales data, such as AstraZeneca, which started the trend in Q1. As a recurring feature, PharmAsia News combs through quarterly earnings reports to bring together the earning season's Asia highlights.
Abbott, Baxter, Bristol-Myers Squibb: Emerging Markets Earnings Roundup (Part 1 of 3)
A push in emerging markets continued in the second quarter with Big Pharma reporting flat U.S. sales and a challenging payer environment in Europe, with many reallocating resources in Asia and forming more Asia partnerships. As a recurring feature, PharmAsia News combs through quarterly earnings reports to bring together the earning season's Asia highlights.